Article
Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib
Authors:
Kenta Nio,
Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Kenta
MD, PhD
Kenji Tsuchihashi,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Kenji
MD, PhD
Keisuke Taguchi,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Keisuke
MD
Tomoyasu Yoshihiro,
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Tomoyasu
MD
Kyoko Yamaguchi,
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Kyoko
MD, PhD
Mamoru Ito,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Mamoru
MD, PhD
Shohei Moriyama,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Shohei
MD
Mitsuhiro Fukata,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Mitsuhiro
MD, PhD
Toshifumi Fujiwara,
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Toshifumi
MD, PhD
Nokitaka Setsu,
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Nokitaka
MD, PhD
Makoto Endo,
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Makoto
MD, PhD
Yoshihiro Matsumoto,
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Yoshihiro
MD, PhD
Yasuharu Nakashima,
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Yasuharu
MD, PhD
Takahiro Wakasaki,
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Takahiro
MD, PhD
Ryuji Yasumatsu,
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Ryuji
MD, PhD
Hiroshi Ariyama,
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Hiroshi
MD, PhD
Hitoshi Kusaba,
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JP
About Hitoshi
MD, PhD
Junji Kishimoto,
Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, JP
About Junji
MA
Koichi Akashi,
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Koichi
MD, PhD
Eishi Baba
Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
About Eishi
MD, PhD
Abstract
Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical practice. We retrospectively analyzed data derived from 29 patients with thyroid cancer or soft tissue sarcoma (STS) treated with lenvatinib (n=10) and pazopanib (n=19). Eight (arterial n=4; venous n=4) thromboembolic events developed in 6 (20%) patients. Thromboembolisms occurred during a mean of 149 (range, 42–847) days from starting TKI. The primary disease progressed in all patients with thromboembolism. The overall survival durations of patientswith and without improved thromboembolism were 572 [95% confidence interval (CI), 225– 918] and 176 (95% CI, 84–394) days, respectively, which did not significantly differ (P=0.33). Patients with and without improved thromboembolism survived after onset for 122 (95% CI, 71–173) versus 27 (95%CI, 21–42) days (P=0.049), which significantly differed. Univariate analysis and variate selection for multivariate analysis selected a history of thromboembolism as the most powerful risk factor for new thromboembolism. In summary, the frequency of thromboembolism in clinical practice was higher than that in previous clinical trials. Furthermore, a history of thromboembolism was a risk factor for the development of new thromboembolism in patients treated with TKI. Thromboembolism developed particularly as the primary disease progressed. Our findings require validation in a large-scale study.
How to Cite:
Nio K, Tsuchihashi K, Taguchi K, Yoshihiro T, Yamaguchi K, Ito M, et al.. Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib. International Journal of Surgery: Oncology. 2020;5(4):e89. DOI: http://doi.org/10.1097/IJ9.0000000000000089
Published on
26 Jun 2020.
Peer Reviewed
Downloads
